Seattle BioMed President and Director Alan Aderem has written an op-ed for the Seattle Times about the critical importance of NIH funding in developing infectious disease research . Join us in seeking congressional action.   >>Learn More

Professor John Aitchison is a co-recipient of a $10.9 million grant from the NIH’s Institute of General Medical Sciences to establish a new Biotechnology Resource to aid researchers in interpreting complex biological systems, such as cancer and infectious diseases.   >> More

Mapping a Killer

Mapping a Killer
Someone dies from tuberculosis every 20 seconds, yet there's still no effective vaccine. Our groundbreaking map of the Mycobacterium tuberculosis gene regulatory network lays the foundation for new treatments. >>Learn More

Unlocking Malaria

Unlocking Malaria
Victims of cerebral malaria often die from malaria-induced blood clots. Seattle BioMed’s Joe Smith, Ph.D., and a global team, pinpointed the lock-and-key mechanism that allows clots to form. Learn more >>

At Seattle BioMed, we are tipping the fight against infectious disease.  We put HIV, tuberculosis and malaria scientists under one roof with systems biology experts to work on our only agenda: to do science that accelerates progress and improves lives. >> Watch our video

 

Novel Agents Capable of Killing TB Identified

Researchers in the lab of Professor David Sherman, Ph.D., have developed and screened several compounds with antibacterial properties capable of destroying Mycobacterium tuberculosis (Mtb), the bacterium that causes TB. These compounds, called anti-folates, block the folate pathway, which is responsible for the synthesis of the essential cellular building blocks, without which Mtb cannot survive. The results of this study were published in the June issue of the journal Chemistry and Biology.  More >>

A Novel Malaria Vaccine Approach

In September 15th's R&D Magazine, Dr. Stefan Kappe defines the struggles of current malaria vaccines in clinical trials. In order to create a successful malaria vaccine, Kappe and his team developed a GAP vaccine strategy that prohibits the parasite from leaving the liver and causing infection. More>>

News + Events

Connect with Us

Stay informed. Sign up for our email newsletter

Find out what the BUZZ is all about.

visit our labs
[ Lab to Life Tour ]